Considering the emerging role of mast cells in NDDs such as AD and MS (Vermersch et al., 2022; Dubois et al., 2023), inhibiting c-KIT signaling on mast cells thus represents a potential mechanism for reducing inflammation in these disorders. The gene discussed is KIT; the disease is myeloid sarcoma.